Association of baseline characteristics with clinical outcomes of tirzepatide treatment in Japanese patients with obesity disease: A subgroup analysis of the SURMOUNT-J trial.

ABSTRACT:

Aims

This analysis aimed to assess the influence of selected baseline factors on tirzepatide treatment response in Japanese patients with obesity disease.

Materials and methods

This was a prespecified subgroup analysis of the SURMOUNT-J trial. Japanese adults with obesity disease, excluding diabetes, were randomised 1:1:1 to receive once-weekly subcutaneous tirzepatide 10 mg, tirzepatide 15 mg, or placebo. Key safety and efficacy outcomes at week 72 were analysed by baseline characteristics, including sex, age (<65, ≥65 years), and body mass index (BMI; <35 kg/m², ≥35 kg/m²). Post hoc analyses were conducted to examine cardiometabolic parameters by subgroup.

Results

Overall, 225 participants were examined (tirzepatide 10 mg: n = 73; tirzepatide 1

SUBMITTER: Yokote K 

PROVIDER: S-EPMC12803658 | biostudies-literature | 2026 Feb

REPOSITORIES: biostudies-literature